bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2010: M F J
2009: D N O S A J J M A M

 
  Other news for:
Alzheimer Disease
Brain
 Resources from HONselect
Potential New Target Found for Alzheimer's Disease
In study on mice, researchers were able to limit effects on brain

By Robert Preidt

WEDNESDAY, Dec. 9 (HealthDay News) -- The low-density lipoprotein receptor may help reduce brain damage caused by Alzheimer's disease, a new study suggests.

Accumulation of amyloid beta-protein (A-beta) plaques in the brain plays a major role in Alzheimer's, and previous research has implicated apolipoprotein E (apoE) in the accumulation of A-beta plaques, according to background information in the study, published in the Dec. 10 issue of Neuron.

"Modulating the function of proteins that control apoE metabolism in the brain will likely alter the extent of amyloid deposition and ultimately affect the disease process," Dr. David M. Holtzman, of the Washington University School of Medicine, said in a news release from the journal's publisher. "We know that low-density lipoprotein receptor binds to apoE, yet its potential role in Alzheimer's disease pathogenesis remains unclear."

In the new study, Holtzman and his colleagues genetically engineered mice that overexpressed low-density lipoprotein receptor, or LDLR, in the brain and bred them with mice engineered to feature key brain changes associated with Alzheimer's disease, including A-beta accumulation.

Overexpression of LDLR decreased brain apoE levels by 50 to 90 percent, resulting in significant reductions in plaque formation and neuroinflammatory responses, the researchers found.

"Our study clearly demonstrates the beneficial effects of LDLR overexpression in the brain on pathogenic A-beta aggregation and subsequent neuroinflammatory responses," Holtzman said. "Given the results from these studies, the therapeutic potential of previously identified compounds and potential new agents, which regulate LDLR in peripheral tissues, merits additional testing in animal models of A-beta amyloidosis."

More information

The U.S. National Institute on Aging has more about Alzheimer's disease.

SOURCE: Cell Press, news release, Dec. 9, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved. URL:http://www.healthscout.com/template.asp?id=633868

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Brain
Alzheimer Disease
Receptors, Lipoprotein
Role
Research Personnel
Medicine
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact